Impedimed Limited (AU:IPD)
ASX:IPD
IPD Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume149.09K
Average Volume (3M)853.05K
Market Cap
AU$30.58M
Enterprise ValueAU$33.67M
Total Cash (Recent Filing)AU$18.85M
Total Debt (Recent Filing)AU$21.93M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,038,747,700
10 Day Avg. Volume551,953
30 Day Avg. Volume853,052
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)3.45
Price to Sales (P/S)5.55
P/FCF Ratio-4.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.04Price Target Upside116.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$16.43M
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn 86.25% gross margin indicates durable unit-level economics and pricing power in the core BIS product line. High gross margins provide structural capacity to fund R&D, sales and support investment, improving the odds of achieving operating leverage over time.
Recurring Revenue PotentialA business model combining upfront device sales with consumables and software-related follow-on revenue supports predictable lifetime customer value. An expanding installed base can produce durable repeat revenue and higher margin streams, strengthening revenue visibility.
Manageable LeverageA debt-to-equity ratio around 0.71 signals conservative leverage relative to risky outcomes, preserving financial flexibility. This balance sheet posture supports continued investment in commercialization or product development without immediate refinancing pressure.
Bears Say
Negative Operating Cash FlowPersistently negative operating cash flow undermines self-funding: it forces reliance on external financing or equity issuance to cover working capital and growth. Over months, this constrains investment in sales/clinical adoption and increases liquidity risk if not addressed.
Weak ProfitabilityNegative EBIT and net margins show operating costs eat into a high gross margin base, limiting the company's ability to convert sales into durable profits. Structural cost pressures or insufficient scale could keep profitability weak absent sustained revenue acceleration or cost control.
Worsening Free Cash Flow TrendA -20.73% free cash flow growth rate indicates deteriorating cash generation and shrinking runway. This trend raises medium-term funding and execution risk, potentially forcing cutbacks or dilutive capital raises if operational cash performance does not improve.
Impedimed Limited News
IPD FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is AU$30.58M.
When is Impedimed Limited’s upcoming earnings report date?
Impedimed Limited’s upcoming earnings report date is Aug 27, 2026 which is in 150 days.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Feb 20, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of -AU$0.002 by -AU$0.004.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Undervalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate is 0.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 2,038,747,700 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of -AU$0.002. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in AU:IPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Impedimed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.04 (116.04% Upside)
AU$0.04 (116.04% Upside)
Blogger Sentiment
Bullish
AU:IPD Sentiment 90%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $20.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
-165.13%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Impedimed Limited
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
IPD Stock 12 Month Forecast
Average Price Target
AU$0.04
▲(116.04% Upside)
Technical Analysis
Compumedics Limited
―
Uscom Limited
―
HeraMED Ltd.
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---